Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings Call Transcript

Scott Henry: I completely understand, and congratulations again, Pat. Great career. But I think you got a couple more chapters to write, but it’s been great to watch.

Operator: Thank you. We’ve reached the end of our question-and-answer session. I’d like to turn the floor back over to Pat for any further or closing comments.

Patrick McEnany: Thank you. In conclusion, our dedication to pioneering solutions for rare diseases remains unwavering. As we approach 2024 with eagerness, we are well poised to leverage our strengths, maximize the potential of our promising product portfolio and enhance the lives of patients grappling with rare diseases. I want to thank you for your steadfast support over the years, and here’s to a future brimming with boundless potential under the stewardship of Rich Daly. Thank you.

Operator: Thank you. That does conclude today’s teleconference and webcast. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.